Pfizer to end licence deal with Syros for blood disorder therapies
SYROS Pharmaceuticals said on Friday (Jul 22) Pfizer will terminate a licence deal between the companies related to the development of novel therapies for two blood disorders.
Shares of Syros were down 5.7 per cent in trading after the bell.
The termination will end the company’s more than three-year long collaboration with sickle cell disease drugmaker Global Blood Therapeutics (GBT) that Pfizer bought in a US$5.4 billion deal last August.
The partnership for sickle cell disease and beta thalassemia - diseases that affect the production and nature of hemoglobin in the blood is set to end on Oct 16, the company said.
Syros “intends to seek to identify a new out-licensing partner for its sickle cell disease program,” it added. REUTERS
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Apple nears deal with OpenAI to put ChatGPT on iPhone
Soyoil jumps on bets US tariffs to include Chinese cooking oil
Why companies are nervous about the consumer
Apple says no major app developers accept new outside payments
Shein steps up London IPO preparations amid US hurdles to listing, sources say
Apple scores win in labor case involving fired retail workers